HC Wainwright & Co. Maintains Buy on AEON Biopharma, Lowers Price Target to $1.2
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Douglas Tsao maintains AEON Biopharma (AMEX:AEON) with a Buy and lowers the price target from $5 to $1.2.
HC Wainwright & Co. analyst Douglas Tsao maintains AEON Biopharma (AMEX:AEON) with a Buy and lowers the price target from $5 to $1.2.